G. Giardina

发表

Sentinel Lymph Node and Breast Cancer Staging: Final Results of the Turin Multicenter Study

P. Sismondi, M. Massobrio, G. Bisi, 2000, Tumori.

Early Detection of Breast Cancer Recurrences through Periodic follow-up - is it Useless?

P. Sismondi, S. Ciatto, M. R. del Turco, 1985, Tumori.

Epidoxorubicin and paclitaxel as primary chemotherapy for T > 3 cm and T4 breast cancer patients.

D. Katsaros, M. Massobrio, S. Danese, 2000, Anticancer research.

Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma

P. Sismondi, D. Katsaros, E. Diamandis, 1995, Cancer.

Antiemetic efficacy of granisetron in patients with gynecological malignancies

P. Sismondi, A. Lissoni, S. Danese, 1997, Anti-cancer drugs.

The Emerging Role of Amino Acids of the Brain Microenvironment in the Process of Metastasis Formation

F. Cutruzzolà, A. Macone, A. Paone, 2021, Cancers.

Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker

B. R. Hoffman, D. Katsaros, A. Scorilas, 2002, British Journal of Cancer.

Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker.

D. Katsaros, G. Yousef, A. Scorilas, 2001, Cancer research.

Survival of women with advanced ovarian cancer and complete pathologic response at second‐look laparotomy

F. Parazzini, P. Guarnerio, G. Scarfone, 1996, Cancer.

Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimen.

F. Parazzini, G. Scarfone, G. Bolis, 1994, European journal of cancer.

Prognostic value of estrogen receptors determined by radiochemical vs. histochemical methods in breast cancer

G. Voglino, P. Sismondi, P. Zola, 2005, Breast Cancer Research and Treatment.

Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.

M. Franchi, F. Parazzini, G. Scarfone, 2001, Gynecologic oncology.

Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design.

P. Bruzzi, V. Lorusso, A. Bottini, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concurrent abnormal expression of erbB-2, myc and ras genes is associated with poor outcome of ovarian cancer patients.

P. Sismondi, D. Katsaros, P. Zola, 1995, Anticancer research.

Anthracycline-based preoperative chemotherapy plus lapatinib and trastuzumab or both in HER2-positive breast cancer: Preliminary cardiac safety report of the CHER LOB trial.

D. Amadori, L. Cavanna, P. Conte, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P105 Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer

P. Neven, A. Monnier, N. Bundred, 2005 .

COMPLICATIONS OF LYMPHADENECTOMY IN ENDOMETRIAL CANCER. RESULTS OF A PROSPECTIVE RANDOMIZED MULTICENTRIC CLINICAL TRIAL

M. Franchi, F. Parazzini, N. Ragni, 2004, International Journal of Gynecologic Cancer.